SCHEMBL16369869

SCHEMBL16369869

[c]1ncnc(-c2nccs2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.38
ADORA2A P29274 3/20 0.38
RAB9A P51151 5/20 0.35
LOXL2 Q9Y4K0 1/20 0.34
CYP2A6 P11509 1/20 0.34
NPC1 O15118 4/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 2/20 0.33
ADORA1 P30542 2/20 0.33
RECQL P46063 1/20 0.33
HSP90AA1 P07900 1/20 0.33
TSHR P16473 1/20 0.32
NOS1 P29475 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ADRB2 P07550 1/20 0.32
SMPD3 Q9NY59 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11240898 0.73
SCHEMBL16112970 0.73 PDPK1 (0.45) PDPK1ADORA2ARAB9ALOXL2CYP2A6
SCHEMBL533593 0.71 PDPK1 (0.39) PDPK1ADORA2ARAB9ALOXL2CYP2A6
SCHEMBL292280 0.69 HSP90AA1 (0.49) PDPK1ADORA2ARAB9ALOXL2CYP2A6
SCHEMBL102331 0.68 PDPK1 (0.59) PDPK1ADORA2ARAB9ALOXL2CYP2A6
SCHEMBL556950 0.68 PDPK1 (0.54) PDPK1ADORA2ARAB9ALOXL2CYP2A6
SCHEMBL17701190 0.67 PDPK1 (0.43) PDPK1ADORA2ARAB9ALOXL2CYP2A6
SCHEMBL31556353 0.66 PDPK1 (0.56) PDPK1ADORA2ARAB9ALOXL2CYP2A6
SCHEMBL30534095 0.66 PDPK1 (0.56) PDPK1ADORA2ARAB9ALOXL2CYP2A6
SCHEMBL30632310 0.66 PDPK1 (0.56) PDPK1ADORA2ARAB9ALOXL2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3686190-A1 SYNTHESIS OF THERAPEUTICALLY ACTIVE COMPOUNDS Agios Pharmaceuticals, Inc. (US) 2020-07-29 EP disclosed
EP-3019483-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Agios Pharmaceuticals, Inc. (US) 2016-05-18 EP disclosed
US-20160118598-A1 ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME JNC CORPORATION (JP) 2016-04-28 US disclosed
WO-2015003640-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2015-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160118598-A1 ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME HVCN1, VDAC1, SLC26A3 PDPK1 4680/4885ADORA2A 3352/4885RAB9A 3067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.